An open-label pilot trial of faecal microbiome transfer to restore the gut microbiome in anorexia nervosa: protocol
Authors:
- Brooke C WilsonBWBrooke C Wilson
- José G B DerraikJDJosé G B Derraik
- Benjamin B AlbertBABenjamin B Albert
- Karen S W LeongKLKaren S W Leong
- Ry Y Tweedie-CullenRTRy Y Tweedie-Cullen
- Taygen EdwardsTETaygen Edwards
- Tommi VatanenTVTommi Vatanen
- Hiran ThabrewHTHiran Thabrew
- Wayne S CutfieldWCWayne S Cutfield
- Justin M O'SUllivanJustin M O'SUllivan
Open Access
Abstract
Introduction: Individuals with anorexia nervosa (AN) harbour distinct gut microbiomes compared with healthy individuals, which are sufficient to induce weight loss and anxiety-like behaviours when transplanted into germ-free mice. We hypothesise that faecal microbiome transfer (FMT) from healthy donors would help restore the gut microbiome of individuals with AN, which in turn, may aid patient recovery.Methods: We aim to conduct an open-label pilot study in 20 females aged 16–32 years in Auckland, New Zealand who meet the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria for AN and have a body mass index 13–19 kg/m2. We will recruit four healthy, lean, female donors, aged 18–32 years, who will undergo extensive clinical screening prior to stool donation. Faecal microbiota will be harvested from donors and double encapsulated in delayed release, acid-resistant capsules. All participants will receive a single course of 20 FMT capsules (five from each donor) which they can choose to take over two or four consecutive days. Stool and blood samples will be collected from participants over a period of 3 months to assess their gut microbiome profile, metabolome, levels of intestinal inflammation and nutritional status. Our primary outcome is a shift in the gut microbiome composition at 3 weeks post-FMT (Bray-Curtis dissimilarity). We will also monitor participants’ body composition (whole-body dual-energy X-ray absorptiometry scans), eating disorder psychopathology, mental health and assess their views on, and tolerability of, treatment. All adverse events will be recorded and reviewed by an independent data monitoring committee.Ethics and dissemination: Ethics approval was provided by the Central Health and Disability Ethics Committee (Ministry of Health, New Zealand, 21/CEN/212). Results will be published in peer-reviewed journals and presented to both scientific and consumer group audiences.Trial registration number: ACTRN12621001504808.Keywords
Funding Information
- Rockfield Trust (Award/Grant no: NA)
This publication has 67 references indexed in Scilit:
- World Medical Association Declaration of HelsinkiJAMA, 2013
- RETRACTED ARTICLE: Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coliInternational Journal of Obesity, 2013
- Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic SyndromeGastroenterology, 2012
- Mortality Rates in Patients With Anorexia Nervosa and Other Eating DisordersArchives of General Psychiatry, 2011
- Monitoring Bacterial Community of Human Gut Microbiota Reveals an Increase in Lactobacillus in Obese Patients and Methanogens in Anorexic PatientsPLOS ONE, 2009
- Validation and Standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the General PopulationMedical Care, 2008
- Symptom Profile of Major Depressive Disorder in Women with Eating DisordersAustralian & New Zealand Journal of Psychiatry, 2007
- Comorbidity of Anxiety Disorders With Anorexia and Bulimia NervosaAmerican Journal of Psychiatry, 2004
- Intestinal permeability is decreased in anorexia nervosaMolecular Psychiatry, 2003
- The PHQ-9Journal of General Internal Medicine, 2001